Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CODX

Co-Diagnostics Inc

Mar 11 • 04:00PM ET

3.24

-1.16 -26.36 %

Healthcare • Medical Devices • USA • NASD

Today, 4:30 AMNasdaq compliance notice drove 36.36% premarket surge ahead of trading resumption.

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-28.73	Insider Own	8.57%	Shs Outstand	2.10M	Perf Week	39.06%
Market Cap	6.79M	Forward P/E	-	EPS next Y	-12.15	Insider Trans	-	Shs Float	1.92M	Perf Month	45.95%
Enterprise Value	-3.18M	PEG	-	EPS next Q	-3.60	Inst Own	8.87%	Short Float	0.33%	Perf Quarter	-68.87%
Income	-32.18M	P/S	13.31	EPS this Y	43.55%	Inst Trans	-	Short Ratio	0.10	Perf Half Y	-65.63%
Sales	0.51M	P/B	0.13	EPS next Y	42.14%	ROA	-54.95%	Short Interest	0.01M	Perf YTD	-35.94%
Book/sh	24.82	P/C	0.59	EPS next 5Y	31.42%	ROE	-62.12%	52W High	46.50 -93.03%	Perf Year	-78.37%
Cash/sh	5.46	P/FCF	-	EPS past 3/5Y	- -27.40%	ROIC	-79.35%	52W Low	2.05 58.05%	Perf 3Y	-96.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-80.11% 29.07%	Gross Margin	-201.52%	Volatility	34.21% 13.00%	Perf 5Y	-99.20%
Dividend TTM	-	EV/Sales	-6.24	EPS Y/Y TTM	29.16%	Oper. Margin	-6995.70%	ATR (14)	0.48	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.51	Sales Y/Y TTM	-87.84%	Profit Margin	-6336.27%	RSI (14)	54.77	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.81	EPS Q/Q	51.14%	SMA20	30.43%	Beta	-	Target Price	45.00
Payout	-	Debt/Eq	0.04	Sales Q/Q	-29.73%	SMA50	0.09%	Rel Volume	43.99	Prev Close	4.40
Employees	132	LT Debt/Eq	0.02	Earnings	Nov 13 AMC	SMA200	-60.56%	Avg Volume	65.32K	Price	3.24
IPO	Jul 12, 2017	Option/Short	No / Yes	EPS/Sales Surpr.	15.79% -51.53%	Trades		Volume	2,873,279	Change	-26.36%

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CODX

Co-Diagnostics Inc

Upgrade your FINVIZ experience